Dow Jones
37.775,38 +22,07 (+0,06%) Nasdaq
15.601,50 -81,87 (-0,52%) Nikkei 225
37.137,02 -942,68 (-2,48%) EUR/USD
1,0630 -0,0016 (-0,15%) Bitcoin EUR
58.334,28 +361,61 (+0,62%) CMC Crypto 200
1.291,31 +405,77 (+44,80%)
G1 Therapeutics, Inc. (GTHX)
Dopo ore:
| Chiusura precedente | 4,2800 |
| Aperto | 4,3100 |
| Denaro | 4,1500 x 300 |
| Lettera | 4,2100 x 100 |
| Min-Max giorno | 4,0350 - 4,3100 |
| Intervallo di 52 settimane | 1,0800 - 5,0000 |
| Volume | |
| Media Volume | 1.355.179 |
| Capitalizzazione | 217,672M |
| Beta (5 anni mensile) | 1,70 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,9300 |
| Prossima data utili | 01 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 8,50 |
GlobeNewswireG1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium
RESEARCH TRIANGLE PARK, N.C., Oct. 16, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that multiple abstracts have been accepted for poster presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium, held October 27th and 28th in Boston, MA. A copy of the posters will be made available on the G1 Therapeutics website following the presentations here. “The important research being presen
GlobeNewswireBlack Diamond Therapeutics Announces CEO Transition
Current Chairman of the Board and industry veteran Mark Velleca appointed CEO CAMBRIDGE, Mass. and NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with genetically defined cancers, announced that current Chairman of the Board, Mark Velleca, M.D., Ph.D., has been appointed as Chief Executive Officer (CEO) effective immediately. Dr.
- GlobeNewswire
G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Communications Officer Will Roberts will provide a corporate presentation on September 12, 2023, at 9:30 AM EDT during the H.C. Wainwright 25th Annual Global Investment Conference. The webcast of the event will be accessible on the Events & Presentations page of http://www.g1therapeutics.com. About G1 TherapeuticsG1 Therapeutics, In
